CAWM
REGN icon

Capital A Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Capital A Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1
Closed -$634 – 748
2025
Q1 		$634 Hold
1
– – ﹤0.01% 600
2024
Q4 		$712 Buy
+1
New +$839 ﹤0.01% 605

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital A Wealth Management's REGN Position: Q2 2025 in Review

Capital A Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 1 share — an estimated $634 sold.

Capital A Wealth Management first reported a position in REGN in Q4 2024 and held it in 2 quarters. The position peaked at $712 in Q4 2024. 1,203 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

  • Capital A Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Capital A Wealth Management sold 1 Regeneron Pharmaceuticals share in Q2 2025, an estimated $634.
  • Capital A Wealth Management first reported a position in Regeneron Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Capital A Wealth Management's Regeneron Pharmaceuticals position peaked at $712 in Q4 2024.
  • 1,203 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Capital A Wealth Management's 13F filing for Q2 2025, filed 26 Sep 2025.